"In the investing blog, I seek to help you take sound investment decisions free from emotion by sharing my objective insights on markets, sectors, and companies."
Sam Subramanian
Stocks were virtually unchanged last week after jobless claims data and faltering Sino-U.S. relations offset promising COVID-19 vaccine trial results.
Gains in stock prices from progress on COVID-19 vaccines were limited by mixed economic data and the continued rise in COVID-19 cases.
As COVID-19 cases continued to surge, investors sought safety in large-cap technology stocks and pushed the NASDAQ Composite Index to new all-time highs.
Stocks rose as better-than-expected economic data and positive news on an experimental COVID-19 vaccine calmed fears from rising number of COVID-19 cases.
Fears of economic damage from COVID-19 increased. The Fed restricted banks from returning capital to shareholders. Stocks closed near their two-week low.
The AlphaProfit no-load, no-transaction fee growth model portfolio is up 522% since the start of 2009 compared to the 444% gain for its benchmark. The model portfolio will be reconstituted with new recommendations on Saturday, November 19. Learn more about AlphaProfit's Free and Premium Service investment newsletters.
DEC. 1993 to DEC. 2025| Fidelity Agg. Growth | 17.6% |
| Fidelity Growth | 14.6% |
| ETF Agg. Growth | 17.4% |
| ETF Growth | 14.4% |
| ETF Style Rot. (since 2009) | 11.3% |
| S&P 500 | 10.8% |
DEC. 2013 to DEC. 2025| Win Rate | 91% |
| Avg. Holding Period | 2.6 months |
| Avg. Gain | 13.1% |
